-- 根据周一提交给澳大利亚证券交易所的文件，Paradigm Biopharmaceuticals（ASX：PAR）计划在6月份季度推进其注射用戊聚糖硫酸钠治疗膝骨关节炎疼痛的III期临床试验的第112天随访期，这是纳入中期分析数据集的必要条件。 该公司表示，预计该数据集的独立统计分析结果将于8月份左右公布。具体时间取决于独立第三方机构的日程安排和审核流程，最终中期结果很可能要到9月份才能公布。 此次中期分析预计将首次提供注射用戊聚糖硫酸钠治疗膝骨关节炎的疗效和安全性III期临床试验结果。主要终点指标的初步结果预计将于2027年3月季度公布。 该公司股价周一下跌14%，创一年多以来的新低。
Related Articles
Japan
US 10-Year Treasury Yield Leans Higher at 4.32% Pre-Bell; 2-Year Rate Climbs 1.3 Basis Points to 3.79%
Japan
CGI Launching High-security Sovereign AI Platform in Finland For Enterprise and Public Sector Use
$GIB-A.TO
Research
Mizuho Downgrades Adobe to Neutral From Outperform, Adjusts Price Target to $270 From $315
Adobe (ADBE) has an average rating of overweight and mean price target of $321.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ADBE